Recent Company News

• 10:00 AM ET Oct 17, 2025
  

  Transcript Intelligence: I-Mab Business Update Call ($5.50, -1.06)

• 03:22 AM ET Oct 17, 2025
  

  I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

• 04:13 PM ET Oct 16, 2025
  

  Follow-up: I-Mab to undertake strategic transformation to global biotech platform, pursue hong Kong IPO, and rebranding; call at 17:00ET ($6.56, 0.00)

• 04:06 PM ET Oct 16, 2025
  

  I-Mab to undertake strategic transformation to global biotech platform, pursue hong Kong IPO, and rebrand as NovaBridge Biosciences ($6.56, 0.00)

• 04:03 PM ET Oct 16, 2025
  

  I-Mab halted; news pending ($6.56, 0.00)

• 10:02 AM ET Oct 15, 2025
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (210 total)

• 08:46 AM ET Oct 15, 2025
  

  Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

• 11:22 AM ET Oct 13, 2025
  

  StreetAccount Summary - US unusual volume traders

• 08:02 AM ET Oct 07, 2025
  

  Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms